Moderna, Inc. (MRNA) Stock: Price, Forecast & Analyst Target
Moderna, Inc. (MRNA) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $199.33 (+1.29%), as of the Nov 19, 2026 trading session; market cap $80.7B. Expected results Feb 12, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Moderna, Inc. · MRNA · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Moderna sells messenger RNA vaccines and is using the same platform to develop medicines across infectious disease, cancer, rare conditions, cardiovascular disease and autoimmune disorders. Commercial revenue has retreated sharply while research spending and losses remain substantial, so the business now depends on marketed products gaining traction before cash consumption erodes its financial flexibility.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Moderna (MRNA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for being loss-making and burning cash. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 8 of the last 8 reports
- expected results Feb 12, 2027
- Altman Z 8.20 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 33 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $199.33 | |
| Change on the day | +1.29% | |
| 52-week range | $22.28–$280.80 | |
| Market capitalisation | $80.7B | — |
| Price / earnings (trailing) | -11.50 | |
| Shares traded on the day | 8.18M | |
| Beta (volatility vs the S&P 500) | 1.17 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Moderna (MRNA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Moderna (MRNA), and what does it report?
Short answer · as of
Moderna discovers, develops and commercializes messenger RNA vaccines and therapeutics across global markets.
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Its pipeline reaches far beyond respiratory disease, but the reported revenue line currently reflects product sales rather than broad commercial contribution from that pipeline.
That distinction matters: the financial statements measure a product business supporting a much larger research portfolio. Research spending exceeded annual revenue in the latest fiscal period, while the income statement continued to record a deep net loss.
What do the latest results show for Moderna (MRNA)?
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Revenue contracted again in the latest reporting period, yet gross profit returned to positive territory and the operating loss narrowed sharply from the preceding period. Research spending was broadly stable, leaving the company deeply loss-making despite results that exceeded prevailing revenue and earnings expectations.
Management continues to call for annual revenue growth, attributing that outlook to strategic partnerships in the United Kingdom, Canada and Australia and continued growth from mNEXSPIKE. That expectation is not yet demonstrated by the latest reported revenue pattern, and operating cash flow remained negative.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $1.31B | $162M | $0.38 (diluted) |
| Q2 FY2026 | $145M | -$782M | -$1.96 (diluted) |
| Q1 FY2026 | $389M | -$1.34B | -$3.40 (diluted) |
| Q4 FY2025 | $678M | -$826M | -$2.11 (diluted) |
What are the financial strengths and risks for Moderna (MRNA)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Moderna retains a substantial liquidity cushion: cash and investments exceed total liabilities, while cash and short-term investments comfortably exceed debt. The broader liquidity total includes longer-dated investments, making cash and short-term holdings the more conservative measure of readily available funding.
The vulnerability is sustained cash use. Cash and short-term investments have declined across the reported window, operations consumed cash in the latest periods, and a straight-line continuation of recent spending implies limited runway without commercial improvement or financing.
Market value stands far above net cash, so the valuation rests mainly on future product economics rather than balance-sheet support. Negative trailing margins and returns reinforce how much operating repair remains necessary.
Data-derived red flags
- Negative return on equity (-34.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Moderna (MRNA)?
Short answer · as of
The next earnings report is expected on Feb 12, 2027.
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
The next earnings release needs to show a revenue rebound consistent with management’s expected sales phasing. Progress should also appear in mNEXSPIKE growth and in contributions from the United Kingdom, Canada and Australia, while the geographic mix remains broadly balanced between domestic and international markets.
Revenue alone will not settle the issue. Gross profit needs to remain positive, operating losses must keep narrowing, and operating cash use should moderate; otherwise the liquidity cushion will continue shrinking even if reported sales improve.
A recent filing disclosed a material agreement alongside an unregistered equity issuance. Subsequent changes in financing and share count therefore deserve attention alongside operating results.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Moderna compare with its peers?
Short answer
Moderna's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Moderna combines commercial product sales with a messenger RNA pipeline spanning respiratory vaccines, latent viruses, cancer vaccines, regenerative treatments and systemic medicines. That breadth gives the platform several routes to commercial relevance, supported by alliances with pharmaceutical companies, public agencies and foundations.
Its finances still resemble a development-heavy biotechnology business more than a mature vaccine franchise: revenue is volatile, research spending exceeds current sales, and profitability remains distant in prevailing estimates. Forecast ranges widen materially over time, showing substantial disagreement about how much of the pipeline will translate into revenue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $942.04 Nov 19, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| $945.53 Nov 18, 2026 | $97.8B | 95 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $39.43 Nov 18, 2026 | $174B | 87 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 | |
| $50.97 Nov 18, 2026 | $31.4B | 72 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| $247.77 Nov 18, 2026 | $15.9B | 40 5-pillar Nov 18, 2026 | |
| Moderna (MRNA) — this page | $199.33 | $80.7B | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $25.00 – $305.00
- Consensus target
- $143.67
- Median target
- $132.50
Consensus record · Captured .
Measured against a quoted price of $199.33 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 97
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 15
- Other transactions
- 82
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MRNA in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.06% | $13.93M | Added +527.6% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Moderna (MRNA)?
MRNA Healthcare Stock FAQ
Research dated 2026-09-12 (results through Q2 FY2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does mNEXSPIKE matter to Moderna’s revenue outlook?
Management identifies continued mNEXSPIKE growth as a support for expected annual revenue expansion. Its commercial progress is therefore a direct test of whether Moderna can rebuild sales while the broader pipeline remains under development.
How do Moderna’s United Kingdom, Canada and Australia partnerships affect revenue?
Management expects long-term strategic partnerships in those markets to help drive annual growth. Their contribution should appear alongside the anticipated balance between domestic and international revenue.
What is Moderna developing beyond respiratory vaccines?
The messenger RNA pipeline includes candidates targeting latent viruses, cancer, rare conditions, cardiovascular disease, autoimmune disorders, regenerative medicine and pulmonary delivery. These programs broaden the platform opportunity, but current reporting still centers on product sales.
Can product sales finance Moderna’s messenger RNA research program?
Current product revenue does not cover the research burden and wider operating cost base, leaving operations cash consumptive. Existing liquidity provides funding capacity, but continued burn makes commercial progress important to preserving that cushion.
What is the MRNA stock price today?
The last price recorded for Moderna, Inc. (MRNA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MRNA price target?
The analyst consensus price target for Moderna, Inc. (MRNA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 18 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold MRNA
Funds in our ETF coverage that list MRNA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.